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The cholecystokinin (CCK) receptor is known as a receptor that is overexpressed in many human tumors.
The present study was designed to investigate the targeting ability of cyclic CCK analogue in AR42J
pancreatic cells. The CCK analogues, DOTA-K(glucose)-Gly-Trp-Nle-Asp-Phe (DOTA-glucose-CCK) and
DOTA-Nle-cyclo(Glu-Trp-Nle-Asp-Phe-Lys-NH2) (DOTA-[Nle]-cCCK), were synthesized and radiolabeled
with 177Lu, and competitive binding was evaluated. The binding appearance of synthesized peptide with
AR42J cells was evaluated by confocal microscopy. And bio-distribution was performed in AR42J xeno-
grafted mice. Synthesized peptides were prepared by a solid phase synthesis method, and their purity
was over 98%. DOTA is the chelating agent for 177Lu-labeling, in which the peptides were radiolabeled
with 177Lu by a high radiolabeling yield. A competitive displacement of 125I-CCK8 on the AR42J cells
revealed that the 50% inhibitory concentration value (IC50) was 12.3 nM of DOTA-glucose-CCK and 1.7 nM
of DOTA-[Nle]-cCCK. Radio-labeled peptides were accumulated in AR42J tumor in vivo, and %ID/g of the
tumor was 0.4 and 0.9 at 2 h p.i. It was concluded that 177Lu-DOTA-[Nle]-cCCK has higher binding afﬁnity
than 177Lu-DOTA-glucose-CCK and can be a potential candidate as a targeting modality for a CCK receptor
over-expressing tumors.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Several receptors are overexpressed in speciﬁc tumors (1). The
CCK receptor is known as a G-protein-coupled receptor (GPCR) that
was ﬁrst discriminated pharmacologically by the differential af-
ﬁnities of gastrin and CCK. It is overexpressed in various cancer
cells. And its incidence is higher than other cancer in the lung and
pancreatic cancer (2, 3). The afﬁnity of gastrin is a requirement to
distinguish CCK receptor subtype (4). The afﬁnity level of gastrin
with a CCK1 receptor is low, but the afﬁnity level of gastrin with a
CCK2 receptor is higher than the afﬁnity level with CCK1 receptor.
In receptor binding progress, Tyr residues of the peptide have a
critical function in the speciﬁcity of receptor (5). If this residue is
sulfated, the peptide shows a high afﬁnity for CCK1 and CCK2 re-
ceptors. This is displayed in small cell lung cancer rich in CCK2
receptors. However, despite the studies of CCK2 receptor: þ82 42 868 8448.
rmacological Society.
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d/4.0/).expression on several cancer cell, no methods are not approved for
use this receptor in the radiopharmaceutical development (6).
The targeting moiety of the CCK peptide is shown in C-terminal
amino acid sequences Trp-Met-Asp-Phe-NH2 for maintaining the
binding afﬁnity of receptor and preserving the CCK-like peptides
biological activity (7). Hence, the peptide N-terminal region may be
used for labeling with radioisotopes and a number of inﬂuential
CCK analogues have been labeled with many radioisotopes such as
177Lu, 68Ga, 99mTc, 111In, 90Y, 18F or 64Cu for targeting CCK receptor-
expressing cancer cells (8).
Among the available radionuclides, 177Lu decays by a half-life of
6.7 days with the emission of beta-rays (497 keV) and gamma-rays
(208 keV), and it is a fantastic therapeutic radionuclide with great
potential for peptide receptor radionuclide therapy (9). Thus, 177Lu
can check the injected therapeutic radiopharmaceuticals localiza-
tion in body during treatment. The well-known chelating agent of
radiolabeling peptideswith 177Lu is 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) (10). 177Lu presents primarily in 3þ
oxidation state and is stabilized by nitrogen or oxygen.
In this study, we employed cyclic CCK2 as a linker of DOTA to
prepare radiolabeled candidates for CCK receptor targeting. DOTA-nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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peptides by 125I-CCK8 on human pancreatic tumor cells were
evaluated.
2. Materials and methods
2.1. Cell culture
AR42J pancreatic carcinoma cells were purchased from the ATCC
(American Type Culture Collection) and cultured in RPMI-1640
(LONZA, Walkersville, MD, USA), supplemented with 100 units/
mL penicillin, 100 g/mL streptomycin, and 10% fetal bovine serum
(Sigma, Milan, Italy) in 100 mm dishes. Also, the AR42J pancreatic
carcinoma cells were cultured in 5% CO2 atmosphere in air at 37 C
for up to about 90% conﬂuence (11).
2.2. Peptides
The DOTA-[Nle]-cCCK and DOTA-glucose-CCK were synthesized
through the automatedMultiple Biomolecular Synthesizing System
by Peptron® (Daejeon, South Korea). Fmoc-amino acid conjugated
4-Methylbenzhydrylamine (MBHA) resin was used as an anchor
polymeric support for a solid phase synthesis. After removing the
Fmoc protecting group from resin bounded Fmoc-Met-OH under a
standard cleavage condition (20% Piperidine in N,N-
Dimethylformamide). The resulting peptides were cleaved from
the polymeric support by treatment with a mixture solvent of 90%
TFA containing 2.5% Triisopropylsilane (TIS), 2.5% Ethanedithiol
(EDT), 2.5% thioanisole and 2.5% deionized water (TFA:TIS:
EDT:Thioanisole:H2O ¼ 90:2.5:2.5:2.5:2.5). The crude products
were puriﬁed using a Shimadzu HPLC equipped with a Capcell pak
C18 column on a binary gradient system at a ﬂow rate of
1.0 mL min1 using an elution solvent of 0.1% Triﬂuoroacetic Acid
(TFA) in water (A) and 0.1% TFA in acetonitrile (B) with a gradient
elution proﬁle of (B): 0e10% in 2 min; 10e40% in 10 min; and
40e70% in 2 min. The molecular mass was analyzed on an LC-MS
(Fig. 1).
2.3. Radiolabeling
CCK2 analogues were liqueﬁed in a sodium acetate buffer
(50 mM, pH 5.5) to give a 106 mol/mL. The diluted 177LuCl3 solu-
tion (37 MBq) in a 5.5 M HCl was injected into a vial of the peptide
(108 mol) solution to give a ﬁnal volume of 1 mL. And this vial was
heated at 90 C for 30 min. The yield of radio-labeling, the radio-
chemical purity of the radiolabeled compound, and the stability of
the radiolabeled compound were analyzed by a Waters Chro-
matograph equippedwith an X-Terra C-18 column. The columnwas
eluted with a binary gradient systemwith a ﬂow rate of 1.0 mL/min
using an elution solvent of 0.1% TFA and 5% acetonitrile inwater and
0.1% TFA and 5% water in acetonitrile. The gradient elution proﬁle
based on the solution of 0.1% TFA and 5% water in acetonitrile is as
follows: 0%, 5 min; 0e100%, 9 min; 100%, 6 min; 100%, and 2 min
with 100% of 0.1% TFA and 5% acetonitrile in water.
2.4. Receptor binding study
The receptor binding in vitro of the peptides labeled with 177Lu
were investigated on AR42J cells. AR42J cells were cultured in 12-
well plates and incubated with 125I-CCK8 (Perkin Elmer, 370 kBq,
800e10,000 cpm) in a binding buffer. After incubation at room
temperature for 60 min, the cells were washed for three times with
PBS and counted using a gamma-counter to determine the cell
associated radioactivity.2.5. IC50 determination
The 50% inhibitory concentration (IC50) for binding afﬁnity of
CCK analogues on CCKR was investigated on AR42J cells by a
competitive binding assay. AR42J cells were incubated in 12-well
plates. Grown AR42J cells were washed for three times with a
binding buffer. A range of 1012 to 106 M unlabeled peptides were
added with a trace amount of 125I-CCK8 (10,000 cpm/mL) after
15 min incubation at room. The medium was collected and wash
the cells for three times with PBS after incubation at room tem-
perature for 60 min. The cells were solubilized with 1 N NaOH for
10 min. Gamma-counter was used to determine the radioactivity of
cells. GraphPad Prism softwarewas used to calculate the IC50 values
(Version 5.00 for Windows).
2.6. Immunoﬂuorescent confocal microscopy
For the assay of binding moiety of DOTA-[Nle]-cCCK with
CCKR, AR42J cells were cultured in a coverglass-bottom dish.
AR42J cells were treated with 10 mL of DyLight 633 NHS Ester
(Thermo Scientiﬁc, Hudson, NH, USA)-conjugated DOTA-[Nle]-
cCCK for 20 min and a propidium iodide was added for nucleus
detecting. The cells were ﬁxed with 4% CH2O and 3% sucrose for
20 min. The cells were stained for 2 h with a rabbit polyclonal
anti-CCKR antibody and then incubated for 1 h with Alexa Fluor
488 conjugated secondary antibodies. Confocal microscopy is
used to observe the stained cells.
2.7. Biodistribution assay
Six weeks of age male BALB/c nude mice were supplied from
Nara Biotec, Inc. (Seoul, Korea). All mice were housed in wire cages
at 23 ± 2 C and 50 ± 5% humidity, fed standard laboratory chow
(Samyang, Seoul, South Korea), and allowed water ad libitum. All of
procedures relating to the animals and their care conformed to the
Institutional Animal Care and Use Committee at KAERI approved
the protocols and the Guidelines for Animal Experiments.
For AR42J xenograft mice model, harvested AR42J cells
(106 cells/mouse) were subcutaneously injected in the left upper
ﬂank. After inoculation for 7 days, the tumors were developed to
ranging in mass from 0.11 ± 0.082 g. After tail vein injection with
370 kBq of the 177Lu-DOTA-glucose-CCK and 177Lu-DOTA-[Nle]-
cCCK in 100 mL of saline, the study of biodistribution was per-
formed in AR42J xenograft mice. After injection for 2 h, all mice
were sacriﬁced using CO2, and each tissue sample was collected.
Blood samples were collected using cardiac puncture. The tissue
of tumor and normal organs (liver, kidney, spleen, heart, small
intestine, large intestine, lung, and stomach) were excised,
weighed, and counted using a gamma counter. The organ uptake
was calculated as a percentage of the injected dose per gram of
organ tissue (%ID/g). For the experiment using blocking agent,
mice were injected with a cold peptide (108 mol). And after in-
jection for 2 h, a bio-distribution experiment with blocking agent
was performed.
2.8. Statistical analysis
All values are expressed as mean ± standard deviation (SD) with
statistical signiﬁcance analyzed using a Welch's corrected unpaired
Student's t test or one-way analysis of variance using a GraphPad
Prism computer ﬁtting program.
All data are expressed as the mean ± standard deviation with
statistical signiﬁcance analyzed using one-way ANOVA followed by
a StudenteNewmaneKeuls test.
Fig. 1. The synthetic schemes of DOTA-[Nle]-cCCK (A) and DOTA-glucose-CCK (B).
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Nonradioactive peptides were synthesized by solid phase pep-
tide synthesis following the standard Fmoc strategies. The ﬁnal
peptide sequence of DOTA-glucose-CCK was DOTA-K(glucose)-Gly-
Trp-Nle-Asp-Phe, and DOTA-[Nle]-cCCK was DOTA-Nle-Cyclo(Glu-
Trp-Nle-Asp-Phe-Lys-NH2).
The new conjugates, 177Lu-DOTA-glucose-CCK and 177Lu-DOTA-
[Nle]-cCCK, were routinely prepared in a high yield (>98%) by
adding 177LuCl3 to an aqueous solution (pH 5.5 ammonium acetate)
of the peptides at 90 C for 30 min. The HPLC chromatogram of
177Lu-DOTA-glucose-CCK and 177Lu-DOTA-[Nle]-cCCK showed a
retention time of 12.12 min and 12.29 min, respectively (Fig. 2).
The in vitro CCK receptor binding afﬁnities and speciﬁcities of
DOTA-glucose-CCK and DOTA-[Nle]-cCCK were assessed through a
competitive displacement assay using 125I-CCK8 as the radio-
peptide (Fig. 3). It was found that DOTA-glucose-CCK and DOTA-
[Nle]-cCCK were able to compete with 125I-CCK8 bound to AR42J
pancreatic carcinoma cells. In another peptide of CCK, the IC50 value
of DOTA-sCCK8, sulfated cholecystokinin fragment 26e33, is
10.6 nM. However, IC50 values of new cyclic peptides were 11.93 nM
and 1.57 nM for DOTA-glucose-CCK and DOTA-[Nle]-cCCK,
respectively. It seems that the structure using Nle instead of Met
in a CCK analogue has a higher binding afﬁnity than the original
CCK analogue in cyclic structures.Fig. 2. The formula and radiolabeling with 177Lu of DOTA-glucose-CCK (A) and DOTA-[Nle]-c
was not needed. Retention time: 177Lu-DOTA-glucose-CCK at 12.13 min and 177Lu-DOTA-[NWe examined whether cyclic peptide binds with CCKR in
AR42J cells using a confocal microscopy analysis. According to a
confocal microscope analysis, the ﬂuorescence intensity of DOTA-
[Nle]-cCCK as well as CCKR was observed in the cell membrane
(Fig. 4).
The results of the bio-distribution assay of the 177Lu-labeled CCK
peptides in AR42J pancreas tumor xenografted mice are shown in
Fig. 5. They were compared to a group administered non-labeled
peptide (cold peptide). The 177Lu-labeled CCK analogues also
cleared efﬁciently from the bloodstream, with 0.41 ± 0.03% and
0.7 ± 0.01% ID/g remaining at 2 h p.i. The radio labeled cyclic
peptides were accumulated in the tumors at 2 h p.i. (0.4 and 0.9%
ID/g). In a blocking study, the tumor uptake was reduced by a co-
injection of excess cold-peptide.
4. Discussion
The research of cancer treatment is in progress in many
ﬁelds, and many researchers have been interested in radio-
immunotherapy (RIT). In various ﬁelds of research, because of the
physical properties of radiation, a radiation emitted by radioisotopes
has been investigated for medically using (12, 13). Based on this
background, the interest of theranostic compounds is increasing.
Patients are selectedby the diagnostic study todeterminewhether a
person to be treated. After 131I is used for diagnostic imaging andCCK (B). The radiochemical purity of the peptides was over 98% and further puriﬁcation
le]-cCCK at 12.31 min.
Fig. 3. Binding afﬁnity of 125I-CCK8 with CCK receptor (A) and competitive binding of
125I-CCK8 on AR42J cells by treatment of DOTA-glucose-CCK (B) and DOTA-[Nle]-cCCK
(C). The IC50 of DOTA-glucose-CCK was 12.3 nM and of DOTA-[Nle]-cCCK was 1.7 nM
indicating a highly nanomolar binding afﬁnity on the CCK receptor.
Fig. 4. Interaction between DOTA-[Nle]-cCCK and CCK receptor in AR42J pancreatic
cancer cells. AR42J cells were treated with DyLight 633 NHS Ester-conjugated DOTA-
[Nle]-cCCK in the presence (A) or absence (B) of propidium iodide for nucleus
detecting. The cells were stained with rabbit polyclonal anti-CCKR antibody for 2 h and
then incubated with secondary antibodies conjugated with Alexa Fluor 488 for 1 h. The
stained cells were observed by confocal microscopy.
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progress and many studies are being conducted for 177Lu.
The apoptotic effect of radiation emitted by injected radioiso-
topes must be accumulated into a high portion of tumor tissues to
treat cancer, and it is important to ﬁnd a way of targeting (14). To
increase the efﬁciency of the receptor targeting, there are two el-
ements, i.e., the binding afﬁnity with a speciﬁc receptor and the
material stability (15e17). If the binding ability of the receptor
becomes higher, the ability to deliver the labeled radioisotope to
speciﬁc cancer cells becomes excellent. In addition, increasing the
stability of the substance administered increases the binding af-
ﬁnity with the receptor on the cancer cells owing to the reduction
in the material deformation and degradation (10).
To increase the afﬁnity of the injectedmaterial with the receptor,
it is mainly being studied to transform a portion of a known ligand
structure (18). To increase the binding afﬁnity of the drug conjugate
with cancer cells, ligands, binding with selective receptor on cancer
cells, andmodiﬁed researchhavebeen studied. If thebinding afﬁnity
with a receptor is higher than the conventional ligand, it can be used
to transport a radioisotope to cancer cells. To increase the stability of
injection peptides, various methods have been studied. In variety of
ways, the cyclization of the peptide was conducted to enhance the
stability of melanoma targeting peptide (19e21).
In this study, we synthesize the targeting materials of the
cholecystokinin (CCK) receptor. The CCK receptor is known as areceptor that is overexpressed in various tumor cells. Its incidence
is especially higher in lung and pancreatic cancers than other
cancers. Studies on tumor-associated through CCK peptides are
actively performed. However, improved binding afﬁnity with CCKR
in cancer tissue has emerged through research.
Several methods have been studied to improve the binding af-
ﬁnity of the CCK analogues with CCKR in tissue. The glucose
attached to the side chain of Lys was introduced to the N-terminal
region of the CCK targeting moiety to decrease the lipophilicity of
the peptide. Decreasing the lipophilicity of the CCK analogue may
lead to derivatives with improved sensitivity, speciﬁcity, and
pharmacokinetics for the optimal targeting of CCKR-expressing
tumors. There is another way to improve the reliability through
the cyclization of the peptide. The blood stability of cyclized pep-
tide has been demonstrated in studies on the target peptide of
pancreas and melanoma. High stability is connected with high
effectiveness. Actually, the binding afﬁnities of the cyclic structure
CCK peptides were higher than the linear structure CCK peptides.
Bifunctional chelating agents (BFCA) are used for the preparation
of many radiolabeled compounds. In particular, DOTA is able to
strongly chelatemany radionuclides such as 177Lu, 111In, 149Pm, 212Pb,
90Y, and 68Ga.Additionally,177Luemits strongenergyb-rays (497keV)
and g-rays (208 keV), and its half life is short (6.67 day). Thus, 177Lu is
considered a suitable radionuclide for performing therapy with the
imaging of tumors or metastatic deposits. DOTA-glucose-CCK and
DOTA-[Nle]-cCCK were also easily labeled with 177Lu.
In the previous report, the stability of radioisotope labeled
DOTA-[Nle]-cCCK is higher (>98%) than non-cyclic peptide in
Fig. 5. In vivo biodistribution of 177Lu-DOTA-glucose-CCK (A) and 177Lu-DOTA-[Nle]-
cCCK (B). The organ uptakewas calculated as a percentage of the injected dose per gram
of organ tissue (%ID/g). For the blocking experiment, animalswere coinjected 10-8mol of
the cold peptide.
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better than non-cyclic peptide analogue (11).
In accordance with the results, DOTA-[Nle]-cCCK showed a
higher binding afﬁnity than DOTA-glucose-CCK on the CCK recep-
tor. In addition, the in vivo tumor accumulation rate of 177Lu-DOTA-
[Nle]-cCCK is higher than 177Lu-DOTA-glucose-CCK in the AR42J
injected mice xenograft model.
The kidney is the major excretion organ for i.v. injected radio-
labeled peptides, and an improved tumor-to-kidney ratio is
important to decrease the toxicity of radio peptide. Although a lot
of injected 177Lu labeled CCK peptides uptake in the kidney, they
showed a lower uptake and retention in the liver. Because of this,
they can be a high in vivo stability. These results are united with the
previously reported in vitro CCK peptide stability (11).
If DOTA-[Nle]-cCCK is applied to the clinical approach, lung
cancer patients would be diagnosed by SPECT-CT using 177Lu-
DOTA-[Nle]-cCCK after taking a biopsy for the evaluation of CCK
receptor expression. In addition, the diagnosis of lung cancer can be
conﬁrmed, and the tumor burden including metastases can also be
assessed using 177Lu-DOTA-[Nle]-cCCK for functional imaging.
Next, the patients would begin the treatment using high dose of
177Lu-DOTA-[Nle]-cCCK, and the absorbed dose to the tumor and
the toxicities to normal organs would be evaluated by SPECT-CT,
which can make prognosis predictions.
Therefore, the pharmacokinetic characteristics and therapeutic
efﬁcacy of 177Lu-DOTA-[Nle]-cCCK should be evaluated in the next
investigation. If 177Lu-DOTA-[Nle]-cCCK shows fast excretion in the
kidneys, it can be expected to be a good pharmaceutical agent in
further in vivo studies.Conﬂicts to interest
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